Company Overview and News

1
CDNA / CareDx, Inc. 8-K (Current Report)

2018-04-18 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

1
CDNA / CareDx, Inc. 8-K (Current Report)

2018-04-16 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

1
Olerup QTYPE® Receives CE Mark Certification

2018-04-13 globenewswire
BRISBANE, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that Olerup QTYPE, the fastest real time Human Leukocyte Antigen (HLA) typing diagnostic, has received CE Mark approval and is available on both Roche and Applied Biosystems platforms.
Upvote Downvote

 
CareDx Launches HeartCare® for Heart Transplant Recipients

2018-04-10 globenewswire
BRISBANE, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the launch of HeartCare, a comprehensive rejection surveillance solution for heart transplant recipients.
Upvote Downvote

 
CDNA / CareDx, Inc. / Merckle International GmbH - SCHEDULE 13D (AMENDMENT NO. 2) (Activist Investment)

2018-03-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
CDNA / CareDx, Inc. / Merckle International GmbH - SCHEDULE 13D (AMENDMENT NO. 2) (Activist Investment)

2018-03-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
CareDx's (CDNA) CEO Peter Maag on Q4 2017 Results - Earnings Call Transcript

2018-03-23 seekingalpha
Greetings, and welcome to the CareDx Fourth Quarter 2017 Earnings Conference Call. [Operator instructions] As a reminder, this conference is being recorded.
Upvote Downvote

 
CDNA / CareDx, Inc. 10-K (Annual Report)

2018-03-22 sec.gov
cdna-10k_20171231.htm s UNITED STATES
Upvote Downvote

 
CDNA / CareDx, Inc. FORM 8-K (Current Report)

2018-03-22 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
CareDx Reports Fourth Quarter and FY2017 Financial Results

2018-03-22 globenewswire
BRISBANE, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the fourth quarter and full year ended December 31, 2017.
Upvote Downvote

 
CDNA / CareDx, Inc. FORM 8-K (Current Report)

2018-03-01 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2018 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36536 94-3316839 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
Upvote Downvote

 
CDNA / CareDx, Inc. / HIGHLAND CAPITAL MANAGEMENT FUND ADVISORS, L.P. - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
SC 13G/A     SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     SCHEDULE 13G/A (Rule 13d-102) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934     CareDx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Stat
Upvote Downvote

 
CDNA / CareDx, Inc. / HIGHLAND CAPITAL MANAGEMENT FUND ADVISORS, L.P. - SC 13G/A (Passive Investment)

2018-02-15 sec.gov
SC 13G/A     SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     SCHEDULE 13G/A (Rule 13d-102) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934     CareDx, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 14167L103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Stat
Upvote Downvote

 
CDNA / CareDx, Inc. / GAGNON SECURITIES LLC - SC 13G/A (Passive Investment)

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934   (Amendment No. 5)*   CareDx, Inc. (Name of Issuer)   Common Stock, $0.001 par value per share (Title of Class of Securities)   14167L103 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 14167L103